CompletedNCT06644170
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
Medication studyAges 18–85United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 85 years.
- Listed locations
- SeattleSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: November 19, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- University of Washington
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 85 Years
- Official registry ID
- NCT06644170
- Official title
Show the full official title
A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer
Recruitment & locations
CompletedSeattle
Questions about this study
Who is behind this study?
The study sponsor is University of Washington, a university.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin.
Who was this study for?
Listed age limits: 18 years to 85 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me